Literature DB >> 8642659

Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

S R Bartz1, M E Rogel, M Emerman.   

Abstract

Vpr is a 96-amino-acid protein encoded by human immunodeficiency virus type 1 (HIV-1) that prevents proliferation of infected cells. We have established a system for infection of 100% of a T-cell population with HIV and use this system to show that within the context of HIV-1 infection, Vpr is primarily cytostatic rather than cytotoxic. Vpr acts upstream of dephosphorylation of the mitotic cyclin-dependent kinase, and causes infected cells to accumulate in the G2 stage of the cell cycle. However, some HIV-1 infected cells increase in ploidy and size, accumulating DNA to an 8N level. Furthermore, the mechanism of the Vpr mitotic block is qualitatively different from that of G2 DNA damage checkpoint control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642659      PMCID: PMC190074     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

Review 3.  Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53.

Authors:  J W Ludlow
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

4.  Induction of cell differentiation by human immunodeficiency virus 1 vpr.

Authors:  D N Levy; L S Fernandes; W V Williams; D B Weiner
Journal:  Cell       Date:  1993-02-26       Impact factor: 41.582

5.  Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  S M Lang; M Weeger; C Stahl-Hennig; C Coulibaly; G Hunsmann; J Müller; H Müller-Hermelink; D Fuchs; H Wachter; M M Daniel
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

6.  p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.

Authors:  T A Lehman; W P Bennett; R A Metcalf; J A Welsh; J Ecker; R V Modali; S Ullrich; J W Romano; E Appella; J R Testa
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

7.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Simian virus 40 large T-antigen function is required for induction of tetraploid DNA content during lytic infection.

Authors:  T D Friedrich; J Laffin; J M Lehman
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

10.  Evolution of the primate lentiviruses: evidence from vpx and vpr.

Authors:  M Tristem; C Marshall; A Karpas; F Hill
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  114 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

2.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons.

Authors:  S C Piller; G D Ewart; D A Jans; P W Gage; G B Cox
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo.

Authors:  S M Kao; E D Miller; L Su
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

Review 5.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

6.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

8.  Persistent SIV infection of a blood-brain barrier model.

Authors:  Lisa Strelow; Damir Janigro; Jay A Nelson
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

Review 9.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

10.  Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

Authors:  Erik S Zimmerman; Junjie Chen; Joshua L Andersen; Orly Ardon; Jason L Dehart; Jana Blackett; Shailesh K Choudhary; David Camerini; Paul Nghiem; Vicente Planelles
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.